Comparison of insulin glargine and insulin degludec in type 2 diabetes by continuous glucose monitoring system

Comparison of insulin glargine and insulin degludec in type 2 diabetes by continuous glucose monitoring system - Comparison of insulin glargine and insulin degludec in type 2 diabetes by continuous glucose monitoring system

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010715

Enrollment

Registered

2013-05-15

Start date

2013-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Glargine 8week, Degludec 8week Week8,16CGM Degludec 8week, Glargine 8week Week8,16CGM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)type 2 diabetes outpatient once daily Insulin Glargine administrated before dinner or bed time Basal Bolus therapy or Basal supported oral therapy (2)HbA1c: <8.4%

Exclusion criteria

Exclusion criteria: (1)patient with poor glycemic control (2)Type 1 diabetes (3)secondary diabetes (4)unstable diabetic complication active proliferative retinopaty untreated cardiovascular disease (5) Patient hospitalized or changed treartment within three months (6) noncompliance Irregular life (Night shift pursuer) (7)not willing to use CGM, SMBG (8)Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
glycemic variability by continuous glucose monitoring system	—

Secondary

Measure	Time frame
BMI,HbA1c,glycated albumin,1,5-AG QOL(ITR-QOLN),	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026